Should midazolam drug-drug interactions be of concern to palliative care physicians?

Drug Safety

Volumn 36, Issue 9, 2013, Pages 789-790

  Kotlinska Lemieszek, Aleksandra ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPHENOL; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; CYTOCHROME P450 3A; DIAZEPAM; ERYTHROMYCIN; FLUCONAZOLE; FLUNITRAZEPAM; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MIDAZOLAM; RIFAMPICIN; RITONAVIR;

AREA UNDER THE CURVE; DATA BASE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DYING; DYSPHAGIA; GERMANY; HOSPICE; HUMAN; LETTER; PALLIATIVE THERAPY; PHARMACOKINETICS; PHYSICIAN; PRIORITY JOURNAL; TERMINAL CARE; ADVERSE DRUG REACTION; FEMALE; HOSPICE CARE; MALE;

DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPICE CARE; HUMANS; MALE;

EID: 84890215164     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0066-2     Document Type: Letter

References (12)

1. Frechen S, Zoeller A, Ruberg K, Voltz R, Gaertner J. Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf. 2012;35(9):745-58.
2. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55:481-5. (Pubitemid 24192233)
3. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66(5):461-71.
4. Yang J, Atkins WM, Isoherranen N, et al. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther. 2012;91(3):442-9.
5. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79(4):362-70.
6. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298-305. (Pubitemid 23094372)
7. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia. 1996;37(3):253-7. (Pubitemid 26071826)
8. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59(1):7-13. (Pubitemid 26046768)
9. Backman JT, Kivistö KT, Olkkola KT, et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54(1):53-8. (Pubitemid 28189400)
10. Hafner V, Jäger M, Matthée AK, et al. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther. 2010;87(2):191-6.
11. Yamazaki H, Nakamoto M, Shimizu M, et al. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol. 2010;69(6):593-7.
12. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand. 1999;43(5):509-14. (Pubitemid 29232717)